What Programs Are in Sangamo Therapeutics' Pipeline?

Sangamo Therapeutics is a genomic medicine company that develops gene-based therapeutics across several technology platforms. Its disclosed clinical programs target small fiber neuropathy (SFN), Fabry disease, and hemophilia A, with additional therapeutic applications in neurology and oncology. The company also pursues collaborations and partnerships, and its pipeline page lists clinical programs, clinical trials, and partner relationships as distinct categories.

Clinical Programs Listed on Sangamo's Site

Sangamo's own navigation lists three clinical programs under "Programs":

• Small Fiber Neuropathy (SFN)
• Fabry Disease
• Hemophilia A

These are the named clinical-stage programs the company presents to visitors. The site does not, in the material available here, publish phase numbers, enrollment figures, or readout dates for these programs on the pages described.

Technology Platforms Behind the Programs

Sangamo describes a multi-platform approach to gene-based therapeutics, and its site names these platforms:

The company states it uses "deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today's medicine can only offer symptom management at best."

Therapeutic Applications

Beyond the named clinical programs, Sangamo groups its work under therapeutic applications:

• Neurology
• Oncology

These categories sit alongside the clinical programs in the site's structure, indicating where the platforms are being directed. The available material does not map each platform to each application, so treat the pairing as a general orientation rather than a confirmed program-by-program breakdown.

Clinical Trials, Collaborations, and Partners

Sangamo's navigation separates three related areas:

• Clinical Trials — a distinct section from the clinical programs list
• Collaborations & Partners — covering partnership relationships
• Pipeline — the umbrella under which clinical programs appear

If you need to know which programs are partnered versus wholly owned, or which are actively recruiting, the Collaborations & Partners and Clinical Trials sections are the places to check, since the pipeline listing alone does not carry that detail.

Patient-Facing Programs and Policies

Sangamo also publishes patient-oriented content, including:

• Expanded Access Policy
• Bioethics
• Patient Stories — featuring individuals with Fabry disease, hemophilia A, prion disease, and a renal transplant patient

These are not pipeline programs, but they indicate the disease areas where the company has patient engagement: Fabry disease and hemophilia A appear in both the clinical program list and the patient stories.

Corporate Status Affecting the Pipeline

The site's latest news section states: "Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction," and notes that additional information about a Chapter 11 reorganization and asset sales is available through the company's noticing agent at veritaglobal.net/SangamoTherapeutics.

This matters for anyone tracking the pipeline: a Chapter 11 reorganization and asset auction can change which programs continue, which are sold, and who owns them. Before relying on any program list as current, check the noticing agent page and the company's news releases for the status of specific assets.

How to Verify Current Program Status

Because pipeline stages and ownership can shift — especially during a reorganization — use these steps rather than treating any single page as final:

1. Open the Pipeline section for the current list of clinical programs.
2. Cross-check Clinical Trials for trial-level information.
3. Check Collaborations & Partners to see which programs involve partners.
4. Read News Releases under Investors & Media for the most recent program and corporate updates.
5. For asset ownership questions during the Chapter 11 process, consult the noticing agent site listed on Sangamo's news page.

The site does not publish pricing or access terms for these programs, and nothing here should be read as a claim about availability, cost, or eligibility for any therapy.